39
Participants
Start Date
February 29, 2004
Primary Completion Date
March 31, 2013
Study Completion Date
March 31, 2013
Melan-A ELA + Montanide
"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide
"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpG
"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG
"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG+ IL-2
"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
Oncology Department, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne
Division of Oncology at the Geneva University Hospital, Geneva
Collaborators (1)
Ludwig Institute for Cancer Research
OTHER
Centre Hospitalier Universitaire Vaudois
OTHER